Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT + Aidebelimab + Apatinib Neoadjuvant Therapy for Resectable NSCLC
ChiCTR2500111457Phase 2Not yet recruiting
- Sponsor
- Zhongshan Hospital (Xiamen), Fudan University
- Start
- Oct 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab and Rivoceranib in non-small cell lung cancer (NSCLC), sponsored by Zhongshan Hospital (Xiamen), Fudan University. Primary endpoint: Pathological Complete Response (pCR). Planned start Oct 2025; status: not yet recruiting.
02
Drugs
adebrelimabRivoceranib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500111457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111457.